Products

PATHWORK TISSUE OF ORIGIN TEST KIT-FFPE (ORIGIN TEST KIT-FFPE
PATHWORK DIAGNOSTICS
Oncology AI
A molecular diagnostic test that uses microarray-based RNA profiling and a machine learning algorithm to help pinpoint the origin of hard-to-identify tumors, aiding physicians in optimizing cancer therapies.

See all 1 product →

About PATHWORK DIAGNOSTICS

Pathwork Diagnostics was a molecular diagnostics company that focused on developing and commercializing advanced solutions for oncology. This test aimed to provide crucial diagnostic information for effective patient management and treatment planning, enabling more appropriate, cancer-specific treatment by leveraging genomic insights.

The company’s technology combined proprietary genomic analytics on a microarray platform, developed in collaboration with leading cancer centers and universities. Pathwork Diagnostics positioned itself as a key player in the oncology diagnostics market by addressing the critical need for precise cancer diagnostics. The company’s work was intended to bring the routine application of personalized medicine closer to reality in cancer care.

Focus Areas

molecular diagnostics oncology cancer diagnostics tissue of origin testing gene expression profiling

Business Intelligence

TechnologyMicroarray-based RNA profiling, proprietary genomic analytics, Affymetrix GeneChip System

What Physicians Need to Know

Oncology & Cancer of Unknown Primary (CUP)
PATHWORK DIAGNOSTICS specializes in oncology, particularly in addressing Cancer of Unknown Primary (CUP). Their Pathwork® Tissue of Origin Test helps identify the primary site of metastatic or poorly differentiated tumors when standard diagnostic methods are insufficient.
Molecular Diagnostics & Gene Expression Profiling
The company is a developer of molecular diagnostics for oncology, utilizing gene expression profiling technology. Their core technology involves measuring the activity of thousands of genes simultaneously to create a global picture of cellular function.
Tissue of Origin Testing
PATHWORK DIAGNOSTICS developed the Pathwork® Tissue of Origin Test, which measures gene expression levels of over 1,500 to 2,000 genes in tumor samples. This test compares the tumor's gene expression pattern to a panel of 15 known tissue types to identify the primary tumor site.
FDA Clearance & Clinical Validation
The Pathwork® Tissue of Origin Test received FDA approval in 2008 for fresh frozen tumor samples and in 2010 for formalin-fixed paraffin-embedded (FFPE) tumor tissue. It is noted as the only FDA-cleared molecular diagnostic test for tissue of origin. The test has undergone extensive clinical validation, including a multicenter study of 547 specimens, demonstrating high sensitivity (87.8-88%) and specificity (99.4% or greater) in identifying tumor origin.
Physician Tip

For physicians, PATHWORK DIAGNOSTICS' Tissue of Origin Test offers objective genomic information to aid in diagnosing challenging cancer cases, particularly those with an unknown primary site. This can lead to more accurate diagnoses, allowing for more appropriate, site-specific treatment plans and potentially improving patient survival outcomes. The test can change the working diagnosis in 50% of cases and treatment in 65% of patients with difficult-to-diagnose cancers. The test works on both fresh frozen and FFPE tumor samples, which are common clinical specimen types.

While specific current integrations are not detailed in the provided search results, the company's focus on providing diagnostic services suggests that their test results would integrate into a physician's diagnostic workflow, complementing traditional pathology and imaging studies. The use of microarray technology implies a data-driven output that would need to be interpreted in the context of a patient's clinical history.

Products by PATHWORK DIAGNOSTICS

1 product in the directory

PATHWORK TISSUE OF ORIGIN TEST KIT-FFPE (ORIGIN TEST KIT-FFPE
PATHWORK DIAGNOSTICS
Oncology AI
A molecular diagnostic test that uses microarray-based RNA profiling and a machine learning algorithm to help pinpoint the origin of hard-to-identify tumors, aiding physicians in optimizing cancer therapies.

Videos

News, demos, and interviews about PATHWORK DIAGNOSTICS.

Loading videos...

Videos load interactively. If none appear, search YouTube for PATHWORK DIAGNOSTICS →

View all on YouTube

No press coverage or publications on file yet. Know of some? Suggest an edit →

Frequently Asked Questions

PATHWORK Diagnostics specializes in molecular diagnostics for oncology, with a primary focus on their Tissue of Origin Test. This test utilizes gene expression profiling to help identify the likely primary tumor site for cancers of unknown primary (CUP) and metastatic cancers, aiding in more targeted treatment decisions.
The PATHWORK Tissue of Origin Test helps physicians identify the probable tissue of origin for CUP, which is crucial for guiding treatment strategies. By providing molecular insights into tumor lineage, it can help oncologists select more appropriate and effective therapies, potentially improving patient outcomes.
While specific current regulatory statuses would need direct verification, molecular diagnostic tests like the PATHWORK Tissue of Origin Test are typically offered through CLIA-certified laboratories. Historically, such tests have often been Laboratory Developed Tests (LDTs), which fall under CLIA and CAP regulations, though FDA oversight for LDTs has been a evolving area.
Information on the current pricing structure and specific reimbursement options for the PATHWORK Tissue of Origin Test would require direct inquiry with PATHWORK Diagnostics or their authorized representatives. Reimbursement for molecular diagnostic tests can vary based on payor, medical necessity, and specific coding.
PATHWORK Diagnostics provides scientific and clinical support to healthcare professionals, which typically includes access to medical affairs teams, interpretation guides for test results, and educational resources. This support aims to assist in the proper utilization and understanding of their molecular diagnostic offerings.
PATHWORK Diagnostics was acquired by Response Genetics in 2010, which was subsequently acquired by Biocare Medical in 2015. Therefore, the long-term stability and service for the PATHWORK Tissue of Origin Test would be under the purview of Biocare Medical.

Related Companies

Spectrum Dynamics Medical is a pioneering medical device company focused on transforming nuclear medicine from analog to digital technology. They specialize in developing high-definition, solid-state based nuclear imaging technology, including digital SPECT (Single Photon Emission Computed Tomography) and SPECT/CT systems. Their products aim to meet the clinical needs and workflow demands of diagnostic imaging departments […]

Siemens Medical Solutions USA, Inc., operating as Siemens Healthineers USA, is a prominent medical technology company with a rich history spanning over 175 years, dedicated to pioneering breakthroughs in healthcare. As a subsidiary of the global Siemens Healthineers AG, the company offers a comprehensive portfolio that is central to clinical decision-making across the entire healthcare […]

Siemens Healthineers is a leading global medical technology company that pioneers breakthroughs in healthcare. The company focuses on medical technology and diagnostics, offering a wide range of products including imaging systems, laboratory diagnostics, and advanced therapies. Their innovations aim to improve patient outcomes and make healthcare more accessible and sustainable. Siemens Healthineers has a strong […]

Perimeter Medical Imaging AI is a medical technology company dedicated to transforming cancer surgery through the use of ultra-high-resolution, real-time, advanced imaging tools. The company’s mission is to address significant unmet medical needs in cancer surgery, particularly concerning positive margins and the resulting need for re-excisions. Their proprietary technology, including the S-Series Optical Coherence Tomography […]

PathologyAILab offers advanced digital cytology services, leveraging a multi-agent AI system for cervical cancer diagnosis. This innovative solution provides comprehensive image analysis to deliver precise and reliable diagnostic insights to healthcare professionals. The service aims to provide rapid results, typically within 2-4 hours, for urgent cases, enabling timely clinical decisions. The process involves submitting digital […]

Varian Medical Systems, now a Siemens Healthineers company, is a global leader in advanced radiation oncology solutions for comprehensive cancer treatment. The company develops and manufactures medical devices and software for treating cancer and other medical conditions using therapies such as radiotherapy, radiosurgery, proton therapy, and brachytherapy. Their product portfolio includes linear accelerators (LINACs), proton […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.